SCHEMBL1034307

SCHEMBL1034307

FC(F)(F)c1cccc(-c2ccc3cccc(NCc4ccccn4)c3n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HTT P42858 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KCNH2 Q12809 3/20 0.43
CTSK P43235 1/20 0.43
IL1B P01584 1/20 0.42
KCNA5 P22460 2/20 0.41
GRIN1 Q05586 3/20 0.41
GRIN2B Q13224 3/20 0.41
KMO O15229 1/20 0.41
SLC40A1 Q9NP59 1/20 0.40
SYK P43405 1/20 0.40
PHGDH O43175 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1034300 0.85 GRM5 (0.44) NPC1RAB9AHTTKCNH2CTSK
SCHEMBL1030355 0.81 KMO (0.39) ALDH1A1KCNH2CTSKGRIN1GRIN2B
SCHEMBL1034688 0.81 SORT1 (0.57) NPC1RAB9AHTTALDH1A1TDP1
SCHEMBL1033950 0.80 CYP3A4 (0.53) HTTALDH1A1GRIN1GRIN2BKDM4E
SCHEMBL17772315 0.79 KMO (0.39) ALDH1A1TDP1KCNH2CTSKKMO
SCHEMBL1034381 0.78 SLC40A1 (0.59) SLC40A1
SCHEMBL1031605 0.75 RXFP1 (0.48) CTSS
SCHEMBL13854087 0.74 CTSS (0.58) ALDH1A1TDP1CTSKKMOKDM4E
SCHEMBL31020173 0.73 MEN1 (0.62) NPC1RAB9AHTTALDH1A1TDP1
SCHEMBL28334006 0.72 ALDH1A1 (0.67) NPC1RAB9AHTTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 NPC1 3386/4885RAB9A 660/4885HTT 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.